862 related articles for article (PubMed ID: 23634720)
21. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
Ellsworth P; Travis M
Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
[TBL] [Abstract][Full Text] [Related]
22. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
Kuo HC
Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
[TBL] [Abstract][Full Text] [Related]
23. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children.
Blackburn SC; Jones C; Bedoya S; Steinbrecher HA; Malone PS; Griffin SJ
J Pediatr Urol; 2013 Dec; 9(6 Pt A):750-3. PubMed ID: 23036518
[TBL] [Abstract][Full Text] [Related]
24. [Botulinum toxin type A in patients with overactive bladder].
Krivoborodov GG; Vasil'ev AV; Shumilo DV; Ivanov AV; Tur EI
Urologiia; 2010; (3):36-40. PubMed ID: 20734876
[TBL] [Abstract][Full Text] [Related]
25. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
[TBL] [Abstract][Full Text] [Related]
26. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity.
Hui C; Keji X; Chonghe J; Ping T; Rubiao O; Jianweng Z; Xiangrong D; Liling Z; Maping H; Qingqing L; Qiuling L; Jiebing H; Tanghai H
Spinal Cord; 2016 Jan; 54(1):46-50. PubMed ID: 26261074
[TBL] [Abstract][Full Text] [Related]
27. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
Abdel-Meguid TA
J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin A for the Treatment of Overactive Bladder.
Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
[TBL] [Abstract][Full Text] [Related]
29. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
[TBL] [Abstract][Full Text] [Related]
30. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F; Nitti V
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study.
Ehren I; Volz D; Farrelly E; Berglund L; Brundin L; Hultling C; Lafolie P
Scand J Urol Nephrol; 2007; 41(4):335-40. PubMed ID: 17763227
[TBL] [Abstract][Full Text] [Related]
32. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
[TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin: a potential alternative to current treatment of neurogenic and idiopathic urinary incontinence due to detrusor overactivity.
Casanova N; McGuire E; Fenner DE
Int J Gynaecol Obstet; 2006 Dec; 95(3):305-11. PubMed ID: 17070528
[TBL] [Abstract][Full Text] [Related]
35. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
Kuo HC
Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses.
Grise P; Ruffion A; Denys P; Egon G; Chartier Kastler E
Eur Urol; 2010 Nov; 58(5):759-66. PubMed ID: 20674149
[TBL] [Abstract][Full Text] [Related]
37. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes.
Okamura K; Nojiri Y; Ameda K; Namima T; Suzuki M; Inoue K; Ogawa T; Gotoh M; Homma Y
Int J Urol; 2011 Jun; 18(6):483-7. PubMed ID: 21488978
[TBL] [Abstract][Full Text] [Related]
38. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children.
Léon P; Jolly C; Binet A; Fiquet C; Vilette C; Lefebvre F; Bouché-Pillon-Persyn MA; Poli-Mérol ML
J Pediatr Surg; 2014 Sep; 49(9):1424-8. PubMed ID: 25148752
[TBL] [Abstract][Full Text] [Related]
39. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
Kuo HC
Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
